THE ESTIMATION OF EFFICIENCY OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OVARIAN CANCER

Abstract

Summary. The article presents the results of a retrospective analysis of the treatment of 111 patients with locally advanced ovarian cancer who received neoadjuvant chemotherapy at the first stage of treatment and those who recieved surgery treatment immediately. Most patients with locally advanced ovarian cancer were in the age range 46-66 years, namely 81% in the main group and 85% - in the control. With neoadjuvant chemotherapy is possible to reduce tumor size, particularly when canceromatosis of the peritoneum, improve resectability of the tumor, and also to increase the frequency of surgical debulking of the tumor. Also, the administration of the neoadjuvant chemotherapy increases resectability of tumors in patients with ascites. Using neoadjuvant chemotherapy increases one-year survival and 5-year survival. Median survival in the study group was 7 months and 5 month - in control group.

Keywords

• locally advanced ovarian cancer, neoadjuvant chemotherapy (nact), adjuvant chemothe¬rapy (act), optimal cytoreduction, ascites, panhysterec¬tomy, supravaginal uterine amputation